Integrating immunotherapy in the treatment of resectable gastric cancer: Are we on the right track?

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-03-14 DOI:10.1016/j.medj.2024.10.020

Roberto Pazo-Cid, Paula Gomila Pons

引用次数: 0

Abstract

Long et al.¹ evaluated neoadjuvant (NAT) cadonilimab plus FLOT chemotherapy (ChT) in locally advanced gastric (G) and gastroesophageal junction (GEJ) adenocarcinoma, showing a pathological complete response (pCR) rate of 21.1% and an R0 resection rate of 100%. These findings align with other perioperative immunotherapy trials, although challenges remain in optimizing event-free survival (EFS).

查看原文本刊更多论文

结合免疫疗法治疗可切除胃癌：我们走在正确的道路上吗？

Long等人1评估了新辅助（NAT）卡多尼单抗联合FLOT化疗（ChT）治疗局部进展期胃(G)和胃食管结（GEJ）腺癌的病理完全缓解（pCR）率为21.1%，R0切除率为100%。这些发现与其他围手术期免疫治疗试验一致，尽管在优化无事件生存（EFS）方面仍存在挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.